M



Walter Ling, M.D., Publications

UCLA Integrated Substance Abuse Programs

July 2012 to June 2014

(Updated August 2015)

Please note: Many of the articles listed below are available online at no charge. Click on the link and you will be taken directly to the journal or to the article’s PubMed page, which provides an abstract of the article and may provide a link to the full text of the article. If there are no links provided for an article, you still may find the article or its abstract by searching for it online.

Articles with asterisks appeared in the previous ISAP Biennial Report [2010–2012] because they were published online ahead of print during the time period of that report. They are also included here because the hard-copy publication of these articles occurred during the time period of this report, July 2012 through June 2014, which is reflected in their final citation.

Amato, L., Mitrova, Z., & Davoli, M.; Cochrane Drugs and Alcohol Group (Collaborators include Ling, W.). (2013). Cochrane systematic reviews in the field of addiction: Past and future. Journal of Evidence-Based Medicine, 6(4), 221-228. doi: 10.1111/jebm.12067.

Crist, R.C., Clarke, T.K., Ang, A., Ambrose-Lanci, L.M., Lohoff, F.W., Saxon, A.J., Ling, W., Hillhouse, M.P., Douglas Bruce, R., Woody, G., & Berrettini, W.H. (2013). An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology, 38(10), 2003-2010. PMCID: PMC3746708

Crist, R.C., Clarke, T.K., Ang, A., Ambrose-Lanci, L.M., Lohoff, F.W., Saxon, A.J., Ling, W., Hillhouse, M.P., Douglas Bruce, R., Woody, G., & Berrettini, W.H. (2014). An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology, 39(4), 1039. doi: 10.1038/npp.2013.304. PMCID: PMC3924536 (Available March 1, 2015) Correction to: Neuropsychopharmacology (2013) 38, 2003–2010; doi:10.1038/npp.2013.99

Hasin, D.S., O'Brien, C.P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W.M., Crowley, T., Ling, W., Petry, N.M., Schuckit, M., & Grant, B.F. (2013). DSM-5 criteria for substance use disorders: Recommendations and rationale. American Journal of Psychiatry, 170(8), 834-851. PMCID: PMC3767415

Hser, Y.I., Saxon, A.J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., Cohen, A., & Ling, W. (2014). Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction, 109(1), 79-87. doi: 10.1111/add.12333 PMCID: PMC3947022

Hillhouse, M., Canamar, C.P., & Ling, W. (2013). Predictors of outcome after short-term stabilization with buprenorphine. Journal of Substance Abuse Treatment, 44(3), 336-342. PMCID: PMC3545105

Krupitsky, E., Nunes, E.V., Ling, W., Gastfriend, D.R., Memisoglu, A., & Silverman, B.L. (2013). Injectable extended-release naltrexone (XR-NTX) for opioid dependence: Long-term safety and effectiveness. Addiction, 108(9), 1628-1637. doi: 10.1111/add.12208.

Ling, W. (2013). Commentary on Brooner et al. (2013): One-stop shopping-what sells and what doesn't. Addiction,108(11), 1952-1953. doi: 10.1111/add.12340.

Ling, W., Chang, L., Hillhouse, M., Ang, A., Striebel, J., Jenkins, J., Hernandez, J., Olaer, M., Mooney, L., Reed, S., Fukaya, E., Kogachi, S., Alicata, D., Holmes, N., & Esagoff, A. (2014). Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction, 109(9), 1489-1500. PMCID: PMC4127124 doi: 10.1111/add.12608.

Ling, W., Farabee, D., Liepa, D., & Wu, L.T. (2012). The Treatment Effectiveness Assessment (TEA): An efficient, patient-centered instrument for evaluating progress in recovery from addiction. Substance Abuse and Rehabilitation, 2012(3), 129-136. doi:

Ling, W., Farabee, D., Liepa, D., & Wu, L.T. (2013). The Treatment Effectiveness Assessment (TEA). Substance Abuse and Rehabilitation, 4, 73-74. PMCID: PMC3931657 doi: 10.2147/SAR.S48737.

Ling, W., Hillhouse, M., Ang, A., Jenkins, J., & Fahey, J. (2013). Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction, 108(10), 1788-1798. PMCID: PMC3866908  doi: 10.1111/add.12266.

Ling, W., Mooney, L., & Rawson, R.A. (2013). Amphetamine-type stimulants. In B.S. McCrady & E.E. Epstein (Eds.), Addictions: A comprehensive guidebook (2nd ed., Chap. 8). New York: Oxford University Press.

Mooney, L.J., Nielsen, S., Saxon, A., Hillhouse, M., Thomas, C., Hasson, A., Stablein, D., McCormack, J., Lindblad, R., & Ling, W. (2013). Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology. Contemporary Clinical Trials,34(2), 196-204. PMCID: PMC3760415 doi: 10.1016/t.2012.11.002

*Nielsen, S., Hillhouse, M., Mooney, L., Fahey, J., & Ling, W. (2012). Comparing buprenorphine induction experience with heroin and prescription opioid users. Journal of Substance Abuse Treatment, 43(3), 285-290. PMCID: PMC335075 doi: 10.1016/j.jsat.2011.12.009.

Nielsen, S., Hillhouse, M., Thomas, C., Hasson, A., & Ling, W.A. (2013). A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. Journal of Addiction Medicine, 7(1), 33-38. PMCID: PMC3567310 doi: 10.1097/ADM.0b013e318277e92e.

Nielsen, S., Hillhouse, M., Weiss, R.D., Mooney, L., Sharpe Potter, J., Lee, J., Gourevitch, M.N., & Ling, W. (2014). The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. American Journal on Addictions, 23(4), 343-348. doi: 10.1111/j.1521-0391.2013.12105.x. PMCID: PMC4151625

Potter, J.S., Marino, E.N., Hillhouse, M.P., Nielsen, S., Wiest, K., Canamar, C.P., Martin, J.A., Ang, A., Baker, R., Saxon, A.J., & Ling, W. (2013). Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: Findings from Starting Treatment With Agonist Replacement Therapies (START). Journal of Studies on Alcohol and Drugs, 74(4), 605-613. PMCID:PMC3711351

*Raisch, D.W., Campbell, H.M., Garnand, D.A., Jones, M.A., Sather, M.R., Naik, R., & Ling, W. (2012). Health-related quality of life changes associated with buprenorphine treatment for opioid dependence. Quality of Life Research, 21(7), 1177-1183. PMCID: PMC4153754 doi: 10.1007/s11136-011-0027-0

Rosenthal, R.N., Ling, W., Casadonte, P., Vocci, F., Bailey, G.L., Kampman, K., Patkar, A., Chavoustie, S., Blasey, C., Sigmon, S., & Beebe, K.L. (2013). Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction, 108(12), 2141-2149. doi: 10.1111/add.12315.

Saxon, A.J., Hser, Y.-I., Woody, G., & Ling, W. (2013). Medication-assisted treatment for opioid addiction: Methadone and buprenorphine. Journal of Food and Drug Analysis, 21(4), S69-S72. PMCID: PMC3890252 doi: 10.1016/j.jfda.2013.09.037

Saxon, A.J., Ling, W., Hillhouse, M., Thomas, C., Hasson, A., Ang, A, Doraimani, G., Tasissa, G.,Lokhnygina, Y., Leimberger, J., Bruce, R.D., McCarthy, J., Wiest, K., McLaughlin, P., Bilangi, R., Cohen, A., Woody, G., & Jacobs P. (2013). Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug and Alcohol Dependence, 128(1-2),71-76. PMCID: PMC3543467  doi: 10.1016/j.drugalcdep.2012.08.002.

Tai, B., Saxon, A.J., & Ling, W. (2013). Medication-assisted therapy for opioid addiction. Journal of Food and Drug Analysis, 21(4), S13-S15. doi: 10.1016/j.jfda.2013.09.023 PMCID: PMC4175918

Woody, G., Bruce, D., Korthuis, P.T., Chhatre, S., Hillhouse, M., Jacobs, P., Sorensen, J., Saxon, A.J., Metzger, D., & Ling, W. (2014). HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial. Journal of Acquired Immune Deficiency Syndromes, 66(3), 288-293. PMCID: PMC4146664 doi: 10.1097/QAI.0000000000000165.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download